Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist SAN DIEGO, Sept. 18, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy […]
Read Post
Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range
Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range – Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose – – […]
Read Post
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms […]
Read Post
Confo Therapeutics receives €1.7 million grant from VLAIO
Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication. The grant will […]
Read Post
First patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
Mataró, Barcelona, Spain and Charleroi, Belgium, June 4, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia. This first patient was dosed at the […]
Read Post
Safety and immune stimulation data from an intranodal delivery of TriMix mRNA
Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL Niel (Belgium), 1 June 2019 – eTheRNA immunotherapies NV (Niel, Belgium) announces that Dr. Ana Arance, Medical Oncologist at Hospital Clinic de Barcelona, will present safety and immune response data from the E011-MEL study at the ASCO […]
Read Post
Appointment of Chief Financial Officer
Niel (Belgium), 29 May 2019 – eTheRNA immunotherapies NV, the mRNA immunotherapy company, is pleased to announce the appointment of Ulrich Platte as the Company’s Chief Financial Officer. Ulrich will join the company on 3rd June 2019. Ulrich has a broad experience acquired over the last 20 years in different industries including the life sciences, […]
Read Post
Novadip presents data at 30th annual EURAPS Research Council Meeting
Novadip Biosciences presents data at 30th annual EURAPS Research Council Meeting Data demonstrates safety and efficacy of allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration Mont-Saint Guibert, Belgium, 23 May 2019: Novadip Biosciences (“Novadip”), a regenerative medicine company and pioneer in the development of three-dimensional tissue products derived from adipose stem cells […]
Read Post
EyeD Pharma successfully raises €28 million
Fund+, Qbic and a number of respected Belgian entrepreneurs have placed their trust in EyeD Pharma, a Liège-based pharmaceutical company. Its exceptional fundraising of €28 million will enable progress in the development and production of innovative therapeutic solutions in ophthalmology, particularly for the treatment of glaucoma. Liège, 20 May 2019 – EyeD Pharma was created […]
Read Post
Confo Therapeutics raises €30 million in Series A financing
Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The investment was led by BioGeneration Ventures (BGV) and co-led […]
Read Post
Promethera Biosciences completes €39,7 million ($44,4 million) Series D financing
Proceeds will support ongoing clinical evaluation of HepaStem® in ACLF and launch of a clinical trial in late stage NASH set to commence in H1 2019 in Europe with significant further expansion into the US and Asia Mont-Saint-Guibert, Belgium, and Tokyo, Japan, May 7, 2019 – Promethera Biosciences SA, a global innovator in cell-based medicines […]
Read Post
Complete transaction creating Nasdaq-listed company targeting chronic inflammatory and autoimmune diseases
– Developing Oral Therapies with Best-in-Class Potential – – Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and RelapsingRemitting Multiple Sclerosis – – Proceeds of approximately USD 30 million from concurrent financing to fund clinical development pipeline – – Trading to Commence on The Nasdaq Capital Market under Symbol “IMUX” on […]
Read Post